SPG7 and myeloid sarcoma: The anti-hnRNP A1-M9 antibodies localize to SGs, which results in decreased levels of SPG4 and SPG7 mRNA and protein, two clinically relevant targets related to MS, which now have been shown to bind hnRNP A1.